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Abstract
Background: The number of people living with dementia is expected to exceed 130 million by 2050, which will
have serious personal, social and economic implications. Employing successful intervention and treatment strategies
focused on disease prevention is currently the only available approach that can have an impact on the projected
rates of dementia, with risk assessment being a key component of population-based risk reduction for identification
of at-risk individuals. We evaluated a risk index comprising lifestyle, medical and demographic factors (the Australian
National University Alzheimer’s Disease Risk Index [ANU-ADRI]), as well as a genetic risk score (GRS), for assessment
of the risk of progression to mild cognitive impairment (MCI).
Methods: The ANU-ADRI was computed for the baseline assessment of 2078 participants in the Personality and
Total Health (PATH) Through Life project. GRSs were constructed on the basis of 25 single-nucleotide
polymorphisms previously associated with Alzheimer’s disease (AD). Participants were assessed for clinically
diagnosed MCI and dementia as well as psychometric test-based MCI (MCI-TB) at 12 years of follow-up. Multi-state
models were used to estimate the odds of transitioning from cognitively normal (CN) to MCI, dementia and MCI-TB
over 12 years according to baseline ANU-ADRI and GRS.
Results: A higher ANU-ADRI score was associated with increased risk of progressing from CN to both MCI and
MCI-TB (HR 1.07 [95% CI 1.04–1.11]; 1.07 [1.04–1.09]). The GRS was associated with transitions from CN to dementia
(HR 4.19 [95% CI 1.72–10.20), but not to MCI or MCI-TB (HR 1.05 [95% CI 0.86–1.29]; 1.03 [0.87–1.21]). Limitations of our
study include that the ethnicity of participants in the PATH project is predominately Caucasian, potentially limiting the
generalisability of the results of this study to people of other ethnicities. Biomarkers of AD were not available to define
MCI attributable to AD. Not all the predictive variables for the ANU-ADRI were available in the PATH project.
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Conclusions: In the general population, the ANU-ADRI, comprising lifestyle, medical and demographic factors, is
associated with the risk of progression from CN to MCI, whereas a GRS comprising the main AD risk genes was not
associated with this risk. The ANU-ADRI may be used for population-level risk assessment and screening.
Keywords: Alzheimer’s disease, Cognitive aging, Mild cognitive impairment (MCI), Cohort studies, Risk factors
in epidemiology, Multi-state models
Background
Accurate risk assessment for cognitive impairment and
dementia is increasingly important, given the current
lack of effective disease-modifying treatments for
Alzheimer’s disease (AD) and other dementias. Risk as-
sessment tools may be used in both pharmacological
and non-pharmacological trials, in clinics, and for
population-level screening to guide risk reduction strat-
egies [1, 2]. Validated risk assessment tools that can be
administered at very low cost provide methods for
clinicians in low-income countries and regions to assess
dementia risk and apply prevention strategies. Given
current projections of increasing dementia prevalence,
there is an urgent need for validated risk assessment
tools that have been evaluated in well-characterised
samples over long time periods [3]. However, to our
knowledge, established dementia risk tools [4] have not
been evaluated for assessment of risk of mild cognitive
impairment (MCI), which is a key target group for
secondary prevention and pharmaceutical trials. Using a
recently developed risk tool for MCI formulated in the
Mayo Clinic Study of Aging, researchers found that a
basic risk score composed of general demographic (e.g.,
age, education, marital status) and clinical (e.g., diabetes,
hypertension, body mass index [BMI]) features had a
c-statistic of 0.60. An augmented version containing add-
itional variables typically collected in clinical and neuro-
logical examinations (e.g., gain speed, anxiety, Clinical
Dementia Rating Sum of Boxes) had a c-statistic of 0.70
[5]. Further evaluation of this model in an independent
cohort is required.
Recently, there has also been increasing interest in the
evaluation of genetic risk scores (GRSs) for AD and de-
mentia, which have been associated with the develop-
ment of AD and incident MCI [6–9], though they have
limited utility in predicting AD beyond that attained
with basic demographic variables such as age, sex and
education [7, 10, 11]. The number of studies asses-
sing the association of AD GRS with progression between
cognitive states is limited and the findings mixed. These
studies include reports of a significant association between
GRS and progression from cognitively normal (CN) to ei-
ther MCI or late-onset Alzheimer’s disease (LOAD) with a
c-statistic of 0.684 (HR 1.29 [95% CI 1.19–1.39]) [10].
Regarding the conversion from MCI to LOAD, one study
found that participants harbouring 6 or more AD risk
alleles progressed to AD twofold (HR 1.89 [95% CI
1.01–3.56]) more rapidly than those with only 6 alleles
[12], whereas researchers in a second study observed that
an AD GRS composed of 19 loci was associated with the
conversion to dementia (HR 1.59 [95% CI 1.23–2.05]), but
only when apolipoprotein E (APOE) was included in the
risk score [9]. Conversely, researchers in a third study
found no association between progression to dementia
from MCI using an AD GRS composed of 18 loci [13].
Our study had two aims. First, we sought to evaluate
the association of a non-genetic risk index with the pro-
gression from CN to cognitive impairment. Our measure
[14] is a self-report risk index (the Australian National
University Alzheimer’s Disease Risk Index [ANU-ADRI])
that has been externally validated in three cohorts of
older adults in which it was found to be predictive of
AD and dementia [15]. The second aim of the present
study was to compare the ANU-ADRI with a GRS. We
examined the association between cognitive impairment
and the ANU-ADRI and a LOAD GRS, as assessed using
a clinical criterion for MCI or dementia and psycho-
metric test-based criteria for MCI (MCI-TB) in a
community-based cohort of older adults. We first used a
Cox proportional hazards model to investigate the asso-
ciation between the ANU-ADRI and a LOAD GRS and
incident MCI/dementia, and then we extended this
model using multi-state models (MSMs) to account for
backward transitions between cognitive states (i.e.,




Participants were community-dwelling adults residing in
the City of Canberra, Australia, or in the neighbouring
town of Queanbeyan who had been recruited into the
Personality and Total Health (PATH) Through Life pro-
ject, a longitudinal, population-based study of health and
well-being in adults. Cohorts aged 20–24 (20+), 40–44
(40+) and 60–64 (60+) years at baseline were assessed at
4-year intervals for a total of 12 years. The background
and procedures for the PATH study are described else-
where [16]. Written informed consent was obtained
from all participants. This study was approved by the
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human research ethics committee of The Australian
National University.
In this study, we used data from the 60+ cohort with
interviews conducted in 2001–2002 (n = 2551), 2005–
2006 (n = 2222), 2009–2010 (n = 1973) and 2014–2015
(n = 1645). Individuals were excluded if their ethnicity
was not Caucasian (n = 107) or if they had a self-
reported history of stroke, transient ischemic attack,
epilepsy, brain tumours or brain infection (n = 381).
ANU-ADRI risk assessment based on demographic,
lifestyle and medical risk factors
The development of the ANU-ADRI and the method-
ology underlying its computation have been described
previously [15]. The ANU-ADRI can be computed on
the basis of up to 15 predictive variables, 11 of which
are available in PATH, including age (self-report), sex
(self-report), alcohol consumption (calculated according
to National Health and Medical Research Council 2001
guidelines [17] using number of drinks per week, with
light to moderate intake in males being 0.25–20.5 drinks
per week and in females being 0.25–13.5 drinks per
week), education (self-reported number of years of
education), diabetes (self-reported history of diabetes), de-
pression (assessed using the Patient Health Questionnaire
[PHQ-9] [18] following the coding algorithm provided in
the PHQ-9 instruction manual, with a score >10 used as a
cut-off), traumatic brain injury (self-reported history of
traumatic brain injury with loss of consciousness), smok-
ing (self-reported smoking status as current smoker, past
smoker or never smoker), social engagement (constructed
from four domains for marital status, size of social net-
work, quality of social network, level of social activities; a
fifth domain for living arrangements was not available in
PATH and thus was computed pro rata as the average of
the above-mentioned social engagement variables), phys-
ical activity (combined self-reported number of hours per-
forming mild, moderate and vigorous activities, weighted
by multiples of 1, 2 and 3, respectively [19]), cognitively
stimulating activities (assessed as the number of cognitive
activities undertaken in the last 6 months, comprising
reading, writing, playing games or attending cultural
events), and BMI (weight divided by height squared,
expressed in kilograms per square meter). No data were
available for the remaining three predictive variables:
cholesterol, fish intake and pesticide exposure. The ANU-
ADRI is still predictive of the development of dementia,
even when a subset of variables is used [15]. Values for
predictive variables included in the ANU-ADRI for PATH
were selected from baseline measurements or the first oc-
casion on which the variables were measured. To facilitate
interpretation, a constant of +13 was added to the ANU-
ADRI to change the range to from −13 to +19 to 0–32.
Genotyping and genetic risk score
The most significant LOAD risk single-nucleotide poly-
morphisms (SNPs) identified via genome-wide associ-
ation studies (GWASs) [11, 20–24] from 23 loci
(ABCA7, BIN1, CD2AP, CD33, CLU, CR1, EPHA1,
MS4A4A, MS4A4E, MS4A6A, PICALM, HLA-DRB5,
PTK2B, SORL1, SLC24A4-RIN3, DSG2, INPP5D, MEF2C,
NME8, ZCWPW1, CELF1, FERMT2 and CASS4) were
genotyped using TaqMan OpenArray assays (Life
Technologies, Carlsbad, CA, USA) as previously described
[25, 26], in addition to the two SNPs defining the APOE
alleles, which were genotyped using TaqMan assays as
previously described [27]. Using these LOAD risk SNPs,
an explained variance-weighted genetic risk score (EV-
GRS) [28] was constructed, which is the sum of all the risk
alleles across the individual, weighted by minor allele fre-
quency (MAF) and the OR associated with LOAD. The










for the ith patient, where log ORið Þ = the OR for the jth
SNP, MAFij = the MAF for the jth SNP, and Gij = the
number of risk alleles for jth SNP. Individuals with miss-
ing genetic data were excluded (n = 240). We weighted
the LOAD SNPs using the previously reported OR for
LOAD and by the MAF for the CEU reference popula-
tion (Utah residents with Northern and Western
European ancestry; see Additional file 1: Table S1). The
EV-GRS was transformed into a z-score.
Screening and clinical assessment
The screening and clinical assessment methods at waves
1–3 are described elsewhere [29, 30] and are briefly sum-
marised here. At each wave, the same predetermined cut-
off derived from a battery of cognitive tests was used for
inclusion of participants in a sub-study on mild cognitive
disorders and dementia. Participants from the full cohort
were selected for clinical assessment if they had any of the
following: (1) a Mini Mental State Examination (MMSE)
[31] score <25; (2) a score below the fifth percentile score
on immediate or delayed recall of the first list of the
California Verbal Learning Test [32]; or (3) a score below
the fifth percentile on two or more of the Symbol Digit
Modalities Test (SDMT) [33], Purdue Pegboard with both
hands [34] or Simple Reaction Time [35]. At wave 4, par-
ticipants were selected for review if they met any of the
following criteria: (1) MMSE score <25 or ≤2.5th percentile
on one or more cognitive test, (2) previous diagnosis at
waves 1–3, (3) subjective decline ≥25 on the Memory
and Cognition Questionnaire (MACQ) or (4) decline in
MMSE score ≥3 points.
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The criteria for the clinical assessment for cognitive
impairment at waves 1–3 has been published by our
group elsewhere [30]. They involved a structured clinical
assessment for dementia conducted by one of two physi-
cians, a neuropsychological assessment, and the Clinical
Dementia Rating [36], which were used together to for-
mulate a consensus diagnosis.
Owing to the large number of participants screened
for review at wave 4, diagnosis was based on neurologist
review of interview data as outlined below and in Fig. 1.
For each of the 1644 participants with interview data at
wave 4, assessment data were screened for signs of de-
cline on the basis of the following criteria (screen 1): a
previous diagnosis of a cognitive disorder at waves 1, 2
or 3 or either evidence of cognitive impairment on the
MMSE (≤24) or performance on one or more cognitive
tests ≤6.7th percentile at wave 4 (immediate recall task,
delayed recall task, SDMT, F words, A words, Boston
Naming Test, Simple Response Time task, Choice
Response Time task, Purdue Pegboard dominant, Purdue
Pegboard non-dominant, Purdue Pegboard both, Digit
Span Backward, Trail Making Test B, Stroop words, Stroop
colour-word test). Additionally, participants had to show
evidence of either subjective decline (score ≥25 on the
MACQ [32]) or evidence of decline (>3-point decline in
MMSE score since wave 3) or evidence of consistent cogni-
tive impairment over time (MMSE ≤24 at waves 3 and 4).
All data derived from the health survey and cognitive
testing as well as informant interview were collated into
a spreadsheet case file for each participant. This case file
(screen 2) automatically screened each participant for
meeting criteria for any one of the following diagnoses:
Diagnostic and Statistical Manual of Mental Disorders,
Fifth Edition (DSM-5), major neurocognitive disorder
(NCD); DSM-IV dementia; DSM-5 mild NCD; MCI;
age-associated cognitive decline; age-associated memory
impairment; DSM-IV amnestic disorder not otherwise
specified; DSM-IV mild NCD; and DSM-IV other cogni-
tive disorder. Major criteria for meeting most of these
diagnoses were operationalised as any of the following:
(1) concern of self or informant of significant cognitive
decline (MACQ ≥25 or Informant Questionnaire on
Cognitive Decline in the Elderly >3.31 or history of de-
mentia diagnosis); (2) substantial impairment on at least
one cognitive domain relative to wave 4 normative data
(cut-offs less than −2 SD for dementias, less than −1.5
SD for mild cognitive disorders); (3) interference with
independence and instrumental activities of daily living
(IADL; self-reported IADL impairment or Bayer IADL
scale score >3.11 or informant-reported everyday cognitive
difficulties); (4) not exclusively during delirium (cognitive
changes of >6 months’ duration, onset of cognitive
changes preceding informant report of onset of delirium-
like symptoms); and (5) not due to another co-existing
disorder (PHQ9 < 9 and no reported history of schizo-
phrenia or other psychosis). Those meeting criteria for
one or more diagnoses (n = 368) were screened for case
file review by a research neurologist. Diagnoses were made
for 301 of these cases, of which 60 complex cases were
selected for diagnostic consensus based on the follow-
ing criteria: (1) comorbid depression, (2) other comor-
bid psychiatric conditions, (3) stroke and (4) DSM-5
major NCD without memory impairment. Following
consensus diagnosis with a clinician specialising in
psychiatry, the final diagnoses included 85 dementia/
major NCD, 196 mild cognitive disorders (MCI/mild
NCD), and 34 other mild or medically related cognitive
disorders.
Clinically diagnosed MCI was based on the Petersen
criteria at waves 1 and 2 [37], whereas the Winblad
criteria [38] were used at waves 3 and 4. Clinically diag-
nosed dementia was based on the DSM-IV criteria [39]
at all waves. At wave 4, there were 14 participants who
were not interviewed but were known to have dementia
on the basis of informant reports and medical records.
Owing to the small number of individuals classified with
dementia, participants with either MCI or dementia
were grouped into a single MCI/dementia category.
MCI-TB
To complement the clinical diagnosis of MCI, a
broader MCI-TB classification was applied to the entire
PATH sample [40] at each wave on the basis of
education-adjusted cognitive performance (Table 1).
The PATH sample was first stratified by education
(0–12 or 13+ years). Within each of these strata, indi-
viduals were classified as MCI-TB if they scored 1.5
SD below the mean on one or more of the psychomet-
ric tests used to assess the following cognitive do-
mains: perceptual speed measured using the SDMT
[33], episodic memory assessed using the immediate
recall of the first trial of the California Verbal Learn-
ing Test (recall-immediate) [32], working memory
measured using the Digit Span Backward from the
Wechsler Memory Scale [41] and vocabulary assessed
by the Spot-the-Word test [42].
Data analysis
All statistical analyses were performed using R version
3.1.2 software [43]. Because missing values can reduce
power and introduce bias in the resulting estimates,
missing values that were not attributable to attrition for
the predictive variables used in the construction of the
ANU-ADRI and the MCI-TB (see above) were imputed
using an implementation of the random forests algo-
rithm available in the ‘missForest’ package in R [44, 45].
This left 2078 individuals available for analysis.
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Additional file 2: Table S2 shows the proportion of miss-
ing variables for each variable.
We first evaluated the risk of progression from CN to
MCI/dementia using Cox proportional hazards models
with age as the time scale and the ANU-ADRI and
EV-GRS included as predictor variables in the same
model. The outcome of interest in these models was the
time to first diagnosis of MCI/dementia, with those sub-
jects who did not develop MCI/dementia at their last as-
sessment right-censored. HRs and 95% CIs were given for
the time to MCI/dementia analysis. Concordance index
(c-index) for the prediction of conversion from NC to
Fig. 1 Flowchart depicting the process of screening participants for mild cognitive disorders. DSM-IV Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition; DSM-5 Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; MCI Mild cognitive impairment; NCD Neurocognitive
disorder; PATH Personality and Total Health Through Life project
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MCI/dementia was calculated. Cox proportional hazards
models were estimated using the ‘survival’ package in R.
To evaluate a more complex model of disease pro-
gression, MSMs were used to examine the association
between the ANU-ADRI and EV-GRS and transitions
between cognitive states. MSMs allow the modelling of
competing risks and backward transitions between states
(i.e., recovery) [46]. Hidden Markov models can be used
to estimate misclassification error, and the effects of co-
variates can be allowed to vary by transition [46]. The
MSMs used in this analysis modelled cognitive deterior-
ation and cognitive recovery by allowing transitions and
backward transitions between CN, MCI or MCI-TB
states. Backward transitions from dementia were not
Table 1 Characteristics of Personality and Total Health Through Life project cohort for waves 1–4
Wave 1, estimate ± SD Wave 2, estimate ± SD Wave 3, estimate ± SD Wave 4, estimate ± SD
n 2078 1798 1596 1337
Age, years 63 ± 1.5 67 ± 1.5 71 ± 1.5 75 ± 1.5
Female sex, n (%) 1009 (48.5) 870 (48.3) 775 (48.6) 651 (48.7)
Education 14 ± 2.8 – – –
Wave 1 completers 12.7 ± 3.0 – – –
Wave 2 completers 13.1 ± 2.7 – – –
Wave 3 completers 13.5 ± 2.7 – – –
Wave 4 completers 14.2 ± 2.6 – – –
Immediate recall 7.2 ± 2.3 7 ± 2.2 6.7 ± 2.2 5.4 ± 1.9
Digit Span Backward 4.9 ± 2.2 5.1 ± 2.2 5.1 ± 2.2 5.3 ± 2.2
Spot-the-Word test 52.0 ± 6.0 53 ± 5.3 53 ± 5.1 54 ± 5
SDMT 50.0 ± 9.7 50 ± 9.2 48 ± 9.2 46 ± 9.5
ANU-ADRI 9.4 ± 5.9 – – –
EV-GRS 1.6 ± 0.4 – – –
Cognitive status, n (%)
MCI 23 (1.1) 28 (1.6) 35 (2.2) 103 (7.7)
Dementia 0 (0) 0 (0) 7 (0.44) 37 (2.7)
MCI-TB 384 (18.4) 373 (20.7) 347 (21.7) 261 (19.5)
Attrition, n (%)
Death – 57 (2.7) 54 (2.5) 94 (5.8)
Dropout – 280 (13.5) 167 (9.3) 329 (20.6)
Abbreviations: ANU-ADRI Australian National University Alzheimer’s Disease Risk Index, EV-GRS Explained variance-weighted genetic risk score, SDMT Symbol Digit
Modalities Test, MCI Mild cognitive impairment, MCI-TB Test-based mild cognitive impairment
Fig. 2 A four-state model for possible transitions between cognitive states and death. HRs (95% CIs) for the effect of the Australian National
University Alzheimer’s Disease Risk Index on transitions between cognitively normal, mild cognitive impairment, dementia and death are shown.
All estimates are from models adjusting for the explained variance-weighted genetic risk score
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allowed, whereas death was used as a fourth absorbing
state (Fig. 2). Individuals with only a single observation
(i.e., no recorded transitions) were excluded from the
analysis (n = 204). Individuals lost to attrition were
considered right-censored. The ANU-ADRI and the
EV-GRS were included as covariates in the same model.
Maximum likelihood estimates of parameters in the MSMs
were obtained with the Broyden-Fletcher-Goldfarb-Shanno
optimisation method. Normalisation was applied to the
likelihood function to improve numerical stability. Because
the likelihood is maximised using numerical methods, an
input of initial values is required to start the search for a
maximum. MSMs were fitted using ‘msm’ [46] in R, and
multiple models were run using different sets of initial
values to ensure the robustness of the parametric esti-
mates. See Additional file 3 for more details on the struc-
ture of MSMs.
As a sensitivity analysis for the MCI-TB analysis, more
stringent criteria were investigated with MCI-TB based on
a score of 1.5 SD below the mean on two or more of the
above-mentioned psychometric tests. Additionally, we
performed a complete case analysis to ensure that our im-
putation method was not biasing the observed results.
Results
Demographics and other characteristics of the sample
Baseline distributions of education, depression, sex,
ANU-ADRI, raw cognitive tests scores and cognitive
states at each wave for the PATH cohort are described
in Table 1. Participants who completed all four waves of
interviews had a higher level of education than
participants who completed only the wave 1 interview
(t = −6.8, df = 331.3, p < 0.001). Participants were followed
for an average of 9.6 years (after accounting for loss due
to attrition) and a total of 13.9 years. Group differences in
the sub-indices of the ANU-ADRI between CN and either
MCI/dementia or MCI-TB can be found in Additional
file 4: Table S3. The distribution of the ANU-ADRI
and EV-GRS scores is shown in Fig. 3. As expected, the
proportion of individuals classified as MCI/dementia in-
creased over the course of the study, whereas the propor-
tion of individuals classified as MCI-TB remained stable
(Table 1). By wave 4, 36% of the cohort had been lost to
follow-up, with 57, 54 and 94 individuals deceased by
waves 2, 3 and 4, respectively, and an additional 280, 267
and 329 individuals being lost to follow-up for other rea-
sons (e.g., refusal, left catchment area) at waves 2, 3 and 4,
respectively.
Between any two waves, a greater proportion of people
transitioned from CN to MCI-TB (10.5%) than from
unimpaired to MCI (2.6%), indicating that MCI-TB is a
broader categorisation of cognitive impairment. A
smaller proportion of individuals transitioned in the op-
posite direction—from MCI-TB to CN (31.3%)—than
from MCI to CN (44%), indicating that MCI-TB is also a
more stable category (Table 2).
Cox proportional hazards models for incident MCI
A higher ANU-ADRI (indicating greater risk) score was as-
sociated with an increased risk of progression to both MCI/
Dementia and MCI-TB (Table 3). The EV-GRS was not as-
sociated with progression to either MCI/Dementia or MCI-
TB. The interaction between the ANU-ADRI and the EV-
GRS was non-significant for the MCI/Dementia (HR
0.99 [95% CI 0.96–1.01], p = 0.33) and MCI-TB (HR
0.99 [95% CI 0.98–1.01], p = 0.11).
In the sensitivity analysis, using a more stringent MCI-
TB criterion (scoring 1.5 SD below the mean on two or
more tests) confirmed that the ANU-ADRI was associated
an increased risk of progression from CN to MCI-TB (HR
1.08 [95% CI 1.05–1.10], p = < 0.0001). In the complete
















Fig. 3 Distribution of the Australian National University Alzheimer’s Disease Risk Index (ANU-ADRI) and explained variance-weighted genetic risk
score (EV-GRS) within the Personality and Total Health Through Life project cohort. The variable width of the violin plot indicates the probability
density, and the box plot indicates the first, median and third quartiles of the ANU-ADRI and EV-GRS scores
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the MCI/dementia (HR 1.06 [95% CI 1.02–1.09], p = 0.001)
and MCI-TB (HR 1.036 [95% CI 1.01–1.04], p = 0.007)
models.
Multi-state models of transitions
A higher ANU-ADRI score was associated with an
increased risk of transitioning from CN to MCI or MCI-
TB (Fig. 1, Table 4). The probability of transitioning
from CN to either MCI or MCI-TB after 12 years for
individuals scoring 1 SD below the mean on the ANU-
ADRI was 10%, and for individuals scoring 1 SD above
the mean, the probability of transitioning was 20%. A
higher ANU-ADRI score was not associated with transi-
tions from CN, MCI, dementia or MCI-TB to death;
with transition from cognitive impairment to dementia;
or with cognitive recovery from MCI or MCI-TB to CN.
The EV-GRS was associated with an increased risk of
transitioning from CN to dementia, with the probability
of transitioning from CN to dementia for individuals
scoring 1 SD above the mean being 1.3%. The inter-
action between the ANU-ADRI and the EV-GRS was
not significant for any of the transitions for either the
MCI or MCI-TB models.
In the sensitivity analysis, using a more stringent MCI-TB
criterion (Additional file 5: Table S4) confirmed that the
ANU-ADRI was associated an increased risk of progression
from CN to MCI-TB (HR 1.12 [95% CI 1.07–1.17]). For the
complete case analysis (Additional file 6: Table S5), the
ANU-ADRI remained statistically significant for both the
models for transition from CN to MCI (1.06 [1.02–1.09])
and from CN to MCI-TB (HR 1.05 [95% CI 1.01–1.08]).
Discussion
To our knowledge, we report the first concurrent evalu-
ation of a non-genetic risk score and a GRS in the risk
of progression to MCI over a long period in a
population-based cohort. As such, this study provides
much-needed information on the utility of risk assess-
ment tools in evaluating the risk of progression to MCI
in the general population. Using Cox proportional haz-
ards models, we found that a unitary increase in the
ANU-ADRI at baseline was associated with 6% and 4%
increased hazards of transitioning from CN to MCI/de-
mentia and MCI-TB, respectively. Additionally, we used
MSMs to extend the Cox proportional hazards models
to account for backward transitions between cognitive
states and the competing risks of death and dementia.
We observed that a unitary change in the ANU-ADRI was
associated with a 7% increased hazard of transitioning
from CN to either MCI or MCI-TB. In contrast, the EV-
GRS was not associated with transition from CN to cogni-
tive impairment, though it was associated with a 419%
increased hazard of transitioning to dementia from CN.
MSMs are well suited to analysing a more ‘realistic’
model of cognitive decline in which cognitive deterior-
ation and recovery are modelled simultaneously in
addition to misclassification, death and censoring. This
is important in the examination of MCI because
Table 2 Number of transitions between cognitively normal, mild cognitive impairment, dementia and test-based mild
cognitive impairment during the length of the study
To
From CN MCI Dementia Death Censored
MCI and dementia
CN 4459 (86.1%) 137 (2.6%) 32 (0.6%) 189 (3.7%) 359 (6.9%)
MCI 40 (48.2%) 26 (31.3%) 6 (7.2%) 5 (6%) 6 (7.2%)
Dementia 0 (0%) 0 (0%) 5 (71.4%) 2 (28.6%) 0 (0%)
Censored 36 (19.5%) 3 (1.6%) 0 (0%) 8 (4.3%) 138 (74.6%)
MCI-TB
CN 3403 (80.2%) 446 (10.5%) 144 (3.4%) 249 (5.9%)
MCI 321 (31.3%) 524 (51.2%) 52 (5.1%) 127 (12.4%)
Censored 28 (15.1%) 11 (5.9%) 8 (4.3%) 138 (74.6%)
Abbreviations: CN Cognitively normal, MCI Mild cognitive impairment, MCI-TB Test-based mild cognitive impairment
Table 3 Associations between the Australian National University
Alzheimer’s Disease Risk Index and explained variance-weighted
genetic risk scores and cognitive impairment at waves 1–4
MCI/dementia MCI-TB
ANU-ADRIa, HR (95% CI) 1.06 (1.03–1.09)b 1.04 (1.02–1.50)b
EV-GRSc, HR (95% CI) 1.14 (0.98–1.33) 1.04 (0.96–1.12)
C-index (SE) 0.61 (0.03) 0.56 (0.01)
ANU-ADRI 0.60 (0.05) 0.56 (0.02)
EV-GRS 0.53 (0.05) 0.51 (0.02)
Abbreviations: ANU-ADRI Australian National University Alzheimer’s Disease Risk
Index; C-index Concordance index; EV-GRS Explained variance-weighted
genetic risk score
All estimates are derived from models adjusting for ANU-ADRI and EV-GRS
aPer unitary increase in ANU-ADRI
bp < .001
cPer SD increase in EV-GRS
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pathological cognitive change is often not a linear pro-
gression from CN to MCI and finally to dementia; rever-
sions from MCI back to CN are common, which was
also observed in the PATH cohort [30, 47]. Individuals
with a stable progression to MCI are more likely to pro-
gress to dementia than those with an unstable course or
no diagnosis of MCI [47]. A higher ANU-ADRI score is
associated both with an increased risk of transition to
clinically diagnosed MCI and to MCI-TB, suggesting
that it could be useful for assessing an individual’s risk
of developing MCI. Additionally, even in individuals
who revert to CN, the diagnosis of cognitive impairment
may still have prognostic implications because these
individuals have a greater likelihood of progressing to
dementia or MCI than those who remain CN [47]. As
such, individuals with a higher ANU-ADRI are more
likely to revert to MCI or develop dementia in the future
[15]. These results show that the ANU-ADRI may be
used to measure risk reduction for clinically significant
MCI as well as dementia, and it may have implications
for secondary prevention of dementia. However,
although the ANU-ADRI is strongly associated with the
progression from CN to MCI, its predictive ability was
limited (c-index 0.60 for MCI and 0.56 for MCI-TB).
This may be due to the relatively young age of the PATH
cohort and consequently the small number of partici-
pants with MCI and the narrow age range of the sample.
We expect that further validation of the ANU-ADRI in a
slightly older cohort with a higher incidence of MCI or
with a wider age range would show that the ANU-ADRI
has greater predictive ability.
The ANU-ADRI has several strengths [4]. First, the
ANU-ADRI is the only risk assessment tool that has not
been developed by identifying risk factors through the
analysis of a single cohort, and as such the predictive
variables are not optimised to a particular study. The
ANU-ADRI also does not include any risk factors that
require clinical assessments or laboratory tests.
The genetic risk score was observed to be associated
with the transition from CN to dementia, but not with
the transition from CN to MCI or from MCI to demen-
tia. This lack of an association may be a result of the
broad categorisation of MCI rather than MCI subtypes,
such that it would have included participants with cogni-
tive impairment that was not MCI due to AD [48, 49].
This may also explain the reduced risk associated with
both MCI and MCI-TB in our sensitivity analysis. Unfor-
tunately, owing to the small number of participants with
MCI in the PATH cohort, further subgroup analysis
would likely be underpowered to detect an effect. How-
ever, it should be noted that most dementia cases are as-
sociated with mixed pathologies rather than singular
pathologies, suggesting that an AD GRS would be asso-
ciated with both amnestic and non-amnestic MCI [50].
Researchers in previous studies have investigated the
association of AD GRS with MCI. In 3605 participants
(360 MCI, 191 dementia), an AD GRS composed of
APOE + 19 LOAD GWAS variants was associated with
an increased risk of incident MCI and nominally associ-
ated with amnestic and non-amnestic cases [9]. In a sec-
ond study of 2674 participants (347 MCI, 132 LOAD), a
GRS composed of APOE + nine LOAD GWAS variants
was associated with progression from CN to MCI/LOAD
[10]. Lack of replication in this study could be due to
younger and fewer cognitively impaired participants.
Furthermore, inclusion of additional AD risk loci that
were identified to be nominally significant in relation to
AD in GWASs may identify a stronger association [8].
Limitations of our study include the relatively high
level of education of the PATH cohort [16]. Also,
the ethnicity distribution in the PATH cohort is
predominately Caucasian, potentially limiting the
Table 4 HRs (95% CIs) of the Australian National University Alzheimer’s Disease Risk Index and explained variance-weighted genetic
risk scores upon cognitive transition
Transition MCI and dementia MCI-TB
ANU-ADRIa EV-GRSb ANU-ADRIa EV-GRSb
CN to MCI 1.07 (1.04–1.10)c 1.05 (0.86–1.29) 1.07 (1.04–1.09)c 1.03 (0.87–1.21)
CN to dementia 0.61 (0.33–1.13) 4.19 (1.72–10.2)c
CN to death 1.03 (0.94–1.12) 0.70 (0.27–1.84) 1.02 (0.98–1.06) 0.89 (0.69–1.16)
MCI to CN 0.85 (0.11–6.79) 0.95 (0–181.21) 0.71 (0.50–1.00) 0.44 (0.12–1.54)
MCI to dementia 1.02 (0.94–1.10) 1.19 (0.76–1.85)
MCI to death 0.96 (0.83–1.11) 0.87 (0.29–2.63) 1.05 (0.98–1.12) 1.05 (0.65–1.71)
Dementia to death 0.99 (0.90–1.09) 0.78 (0.51–1.19)
Abbreviations: ANU-ADRI Australian National University Alzheimer’s Disease Risk Index, EV-GRS Explained variance-weighted genetic risk score, CN Cognitively
normal, MCI/dementia Mild cognitive impairment or dementia, MCI-TB Test-based mild cognitive impairment
All estimates are derived from models adjusting for the ANU-ADRI and EV-GRS
aPer unitary increase in ANU-ADRI
bPer SD increase in EV-GRS
cp < 0.05
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generalisability of the results of this study to other
ethnicities, and biomarkers of AD were not available
(e.g., cerebrospinal fluid, amyloid-β). Not all the pre-
dictive variables for the ANU-ADRI were available in
PATH, suggesting that the present study may under-
estimate the sensitivity of this tool in predicting in-
dividuals who are at risk of developing cognitive
impairment. However, the validation studies also in-
cluded a subset of the variables contributing to the
ANU-ADRI [15].
Study strengths included the large population-based
sample with high retention rates and 12 years of follow-
up data. The PATH cohort was recruited from a narrow
age band, reducing the impact of age differences on the
findings. This is particularly important because age has
the largest weighting of risk factors in the ANU-ADRI.
Finally, the conservative clinical classifications of MCI/
dementia, based on a thorough clinical assessment and
consensus diagnosis by clinicians using published cri-
teria, were complemented by a broader classification of
MCI (MCI-TB).
Conclusions
Higher ANU-ADRI scores are associated with increased
risk of progressing from CN to MCI. These results com-
plement previous evidence that the ANU-ADRI is predict-
ive of AD and dementia [15]. In comparison, a GRS
comprising the main AD genes was associated with the
development of dementia but was not associated with the
risk of developing MCI. These results provide further sup-
port for using the ANU-ADRI for population-level strat-
egies, individual patient assessment, and for informing
intervention and treatment strategies aimed at delaying or
preventing dementia.
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